Skip to main content

Change of number of shares and votes in Moberg Pharma

The number of shares and votes in Moberg Pharma AB (publ) has increased by 2,068,965 to 13,962,537 during June 2014. Therefore, there are in total 13,962,537 shares and votes in the company as of June 30th, 2014.

The increase is a result of a directed share issue of 2,068,965 shares to a limited group of Swedish and international institutional qualified investors, which was resolved by the board on May 27, 2014 under an authorization from the annual general meeting May 13 2014. The share issue was completed in order for Moberg Pharma to increase its financial flexibility relating to potential acquisition opportunities as well as preparations for licensing and development of product candidates in clinical phase.

About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08.30 am (CET) on June 30th, 2014.

For additional information contact:
Peter Wolpert, CEO
Telephone: +46 (0)70 - 735 71 35


Peter Östling, IR
Mobil: +46 (0)76 – 314 09 78

About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with a direct sales and marketing organization in the U.S. and an extensive distributor network in more than 40 countries. The company’s OTC portfolio includes the brands Kerasal®, Jointflex®, Kerasal Nail™, Domeboro®, Vanquish®, and Fergon®. Kerasal Nail™ (Nalox™ in certain ex-U.S. markets) is the leading product for the treatment of nail disorders in the U.S. and Nordic market. The current portfolio will be supplemented by the acquisition and in-licensing of additional products as well as product development with a focus on innovative drug delivery of proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares (OMX: MOB) are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: